21 February 2019 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (‘AusCann’ or ‘the Company’) is pleased to announce it has entered into a Supply Agreement to purchase cannabis resin from MediPharm Labs Corporation (TSXV:LABS) (OTCQB:MLCPF) (“MediPharm”), Canada’s largest and most experienced supplier of purified, pharmaceutical grade cannabis extracts.
The agreement establishes MediPharm as a new supplier of high-grade cannabis resin to AusCann, with first supply to commence in the coming months. The resin will primarily be used in the manufacture of AusCann’s first product line of hard-shell cannabinoid capsules that address the critical need for stability and consistency of dose in cannabinoid medicines.
For further information please download PDF attached:
Download this document